Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Profil von TheMotleyFool

Blog
The Real Reason XRP Keeps Bouncing Back -- and What Comes Next: https://g.foolcdn.com/editorial/images/872353/a-visualization-of-a-blockchain.jpg
The Real Reason XRP Keeps Bouncing Back -- and What Comes Next

The bearish case against XRP (CRYPTO: XRP), the native token of the XRP Ledger, is arguably getting stronger. The token was primarily used as a bridge currency for fiat transactions on Ripple's

First Trust (MISL) vs. ARK (ARKX): Which Space and Aerospace ETF Reigns Supreme?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/4db1f9dc6b521047b90577456a50b49560e87c49-1401x1251.png?w=800&q=75&fit=max&auto=format
First Trust (MISL) vs. ARK (ARKX): Which Space and Aerospace ETF Reigns Supreme?

ARK Space & Defense Innovation ETF (NYSEMKT:ARKX) provides aggressive, high-beta exposure to space technology, while First Trust Indxx Aerospace & Defense ETF (NYSEMKT:MISL) offers a lower-cost

Missed Out on Nvidia? Here's 1 AI Stock You Can Buy Right Now.: https://g.foolcdn.com/editorial/images/871942/ai7.jpg
Missed Out on Nvidia? Here's 1 AI Stock You Can Buy Right Now.

Sitting here today, with stocks like Micron Technology zooming past a $1 trillion market cap and delivering 10x gains in a year, can make you feel like there is no opportunity left to buy artificial

Capital One's Auto Loan Trends Are Quietly Improving. Why It Matters for the Stock.: https://g.foolcdn.com/editorial/images/871304/22_08_08-a-balance-showing-risk-and-reward-_mf-dload.jpg
Capital One's Auto Loan Trends Are Quietly Improving. Why It Matters for the Stock.

Capital One (NYSE: COF) is changing its business model in a significant way following its acquisition of Discover. The key shift is that it will now issue credit cards and process credit card

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/5d5d57f05229d5e553cc6e2f816603ec4ca01b17-1200x800.png?w=800&q=75&fit=max&auto=format
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG